hotspot -WSS

hotspot

author：knowledge 2025-10-01 18:45:39 - browse：824

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Newly revealed memo details efforts to keep Trump in power following election loss

explore

WSS

After John Oliver segment, STAT readers share their opioid

Medicare Advantage insurers face 0.2% cut to 2025 payments

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Kim Kardashian sparks debate on benefits of full

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Investment in vaccine development is lagging, report finds

leisure time

hotspot

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

CDC overhauls leadership of center that led response to Covid

The high cost of giving birth even with insurance

The history of OxyContin, told through Purdue Pharma documents

Psychedelics group wrestles with new pharma identity

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Medicare proposal to cover medical devices draws a mixed reaction

Target recalls 2.2 million additional candles due to laceration, burn hazards

Medicare details structure of new drug price negotiation program

Reconstructing family trees of blood cells may help predict disease

hotspot

Some of the ways extreme heat will change life as we know it

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Target recalls 2.2 million additional candles due to laceration, burn hazards

FTC sues over Novant Health acquisition of two N.C. hospitals

Timeline: Special counsel's investigation into Trump's handling of classified documents

Health Care Service Corp to buy Cigna Medicare Advantage plans

explore

entertainment

explore

hotspot